April 1, 2021
Teliatry Inc. has been awarded a Phase 1 grant from the National Institutes of Health (NIH) to develop the next generation, miniature, rechargeable Spinal Cord Stimulation (SCS) system for treating chronic pain. This small business innovation research (SBIR) phase 1 grant from the NIH complements in-house development of Teliatry's fully implanted multichannel stimulation and recording platform for the field of neuromodulation and beyond.
While all eyes are fixated on ending the coronavirus pandemic, the public health opioid epidemic still needs to be addressed. In the US alone, the over-prescription of opioids has cost the healthcare system over $500 billion to date and currently approximately 120-150 deaths per day can be attributed to opioid overdose issues. Neuromodulation for pain management, and specifically SCS, is a proven therapy for treating chronic pain but it is still considered the last resort therapy because of the current surgical procedures required for large implants.
In collaboration with Backstop Neural LLC, and University of California at San Deigo (UCSD), Teliatry will build the smallest, rechargeable SCS system in the world that can be implanted using a single incision, minimally invasive surgery. This will enable clinically proven and efficacious SCS therapy to enter mainstream chronic back pain management.
Oct 1, 2020
Teliatry is part of a team led by Teledyne Scientific that is developing a next-generation brain-machine interface system. The program aims to achieve bi-directional communication with the brain at unprecedented spatial and temporal resolution while being completely non-invasive. Teliatry will be performing system integration of the final device in Phase II of this DARPA program. Read more
May 11, 2020
Teliatry has received certification to the ISO 9001:2015 and the ISO 13485:2016 (medical devices) International Quality Standard. Meeting these standards helps ensure that products designed and manufactured by Teliatry are of the highest quality for our customers and patients.
May 5, 2020
DARPA’s BG+ program aims to develop new approaches for treating spinal cord injury by integrating injury stabilization, regenerative therapy, and functional restoration. Working with a team led by Karen Moxon at UC Davis, Teliatry is developing two novel implantable hemodynamic sensors to aid in the recovery of spinal cord injury. Read more
April 15, 2020
The Texas Biomedical Device Center has received a second FDA approval for an early feasibility study, again using Teliatry’s Vagus Nerve Stimulator IPG (ReStore), this time to enhance prolonged exposure therapy for treating Post Traumatic Stress Disorder (PTSD). Read more
March 30, 2020
Nano Retina, an affiliate of Zyvex, has announced the preliminary results for First-in-Human implantation of the NR600 artificial retina device. Rahul Saini, CEO of Teliatry, is the system architect for the NR600 implant. Read more
Feb 20, 2020
Teliatry’s customer, The Texas Biomedical Device Center, has received approval from the FDA to proceed with an early feasibility study using Teliatry’s Vagus Nerve Stimulator IPG (ReStore) to enhance recovery following a spinal cord injury. Read more
